Riitta Veijola

Professor and Chief Physician in Paediatrics

Oulu University Hospital

Finland

Research Interests

Explore related searches

Professors in Finland Professors in Immunology Immunology professors in Finland

Contact this professor

ORCID

Google Scholar

About

Riitta Veijola is a Professor and Chief Physician in Paediatrics at the University of Oulu and Oulu University Hospital in Finland. Her research primarily focuses on type 1 diabetes, including β-cell function, genetic predispositions, and autoantibody profiles. She has authored several recent articles investigating the implications of autoantibodies in diabetes development and the effects of dietary interventions. Additionally, her studies encompass early markers and risks associated with type 1 diabetes in children and newborns.

Riitta Veijola

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Continuous glucose monitor metrics from five studies identify participants at risk for type 1 diabetes development

β-Cell Function and Glucose Tolerance in Persons With Multiple Islet Autoantibodies Randomized to a Gluten-free Diet

Symptomatic Type 1 Diabetes Is Approaching, but When?

Association between anti-capsular IgG levels at birth and risk of invasive group B streptococcus disease in Finnish newborns: a retrospective case–control study

Gestational age at birth and type 1 diabetes in childhood and young adulthood: a nationwide register study in Finland, Norway and Sweden

Characteristics of Type 1 Diabetes Among Patients Carrying the Protective HLA‐DQB1*06:02 Allele

Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles

Identification of monogenic variants in more than ten per cent of children without type 1 diabetes-related autoantibodies at diagnosis in the Finnish Pediatric Diabetes Register

Quantifying the utility of islet autoantibody levels in the prediction of type 1 diabetes in children

Extremely Early Appearance of Islet Autoantibodies in Genetically Susceptible Children

Metformin Versus Insulin for Gestational Diabetes: Cognitive and Neuropsychological Profiles of Children Aged 9 years

Detection of enterovirus RNA in peripheral blood mononuclear cells correlates with the presence of the predisposing allele of the type 1 diabetes risk gene IFIH1 and with disease stage

Heterogeneity in the presentation of clinical type 1 diabetes defined by the level of risk conferred by human leukocyte antigen class II genotypes

Impacts of Data Synthesis: A Metric for Quantifiable Data Standards and Performances

HbA1c as a time predictive biomarker for an additional islet autoantibody and type 1 diabetes in seroconverted TEDDY children

Viral infection-related gene upregulation in monocytes in children with signs of β-cell autoimmunity.

Metformin versus insulin therapy for gestational diabetes: Effects on offspring anthropometrics and metabolism at the age of 9 years: A follow‐up study of two open‐label, randomized controlled trials

INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6‐month treatment with incretin‐based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double‐blind, randomised controlled trials (INVESTDIA)

Extended family history of type 1 diabetes in HLA ‐predisposed children with and without islet autoantibodies

Collaborators (24)

Brigitte Frohnert

Päivi H. Tossavainen

Juha Röning

Amir-Babak Sioofy-Khojine

Paula Vähäsalo

Jarno Kettunen

Sarah Richardson

Sven Sandin

Elísabet Einarsdóttir

Mika Gissler

Åke Lernmark

Mikael Knip

Tiinamaija Tuomi

Päivi Miettinen

Maaret Turtinen

Mark Peakman

sami oikarinen

Harri Niinikoski

Markus Mattila

Bart Keymeulen

Marlena Maziarz

Mikko Lehtovirta

Jorma Ilonen

Sauli Palmu

How do I reach out?

Meet Kite AI